The morning sickness hormone that curbs the urge to drink -- could it treat addiction?
GDF15, the hormone responsible for morning sickness in pregnant women, turns out to dampen the urge to drink alcohol as well. Researchers uncovered this link through a combination of genetic data and animal experiments -- and it immediately raises the question of whether this hormone could open a new avenue for treating alcohol addiction.
GDF15 (growth differentiation factor 15) is a stress hormone secreted by cells in response to cellular damage or metabolic stress. In early pregnancy, levels rise sharply and trigger nausea and reduced appetite by acting on receptors in the brainstem. Evolutionarily, that function is understood as a protective mechanism: by making pregnant women averse to potentially harmful foods, it shields them during a vulnerable period.
What researchers have now discovered is that this same hormone also influences alcohol intake. In mouse experiments, administering GDF15 significantly reduced voluntary alcohol consumption. Genetic analysis of human data showed that variants in the GDF15 gene are associated with differences in alcohol use among people. That suggests the effect is not simply an artifact of animal models but is biologically relevant in humans as well.
The brainstem connection
The mechanism appears to run through the area postrema and the nucleus tractus solitarius in the brainstem -- regions also involved in nausea, satiety, and the processing of toxins. GDF15 binds to the receptor GFRAL in these areas. Notably, GFRAL is expressed almost exclusively in the brainstem rather than broadly across the brain. That narrow expression pattern makes it an appealing target: interventions via GFRAL could potentially be precise, without widespread side effects in other brain regions.
Alcohol misuse and addiction rank among the leading preventable causes of premature death and lost healthy years worldwide. Existing drug treatments -- naltrexone, acamprosate, disulfiram -- work for some patients but not all, and are widely underused. A new mechanism that acts directly on the biological drive to drink could complement the current treatment toolkit.
The findings are published in Science. The obvious next question is whether synthetic GDF15 analogues or GFRAL agonists are safe and effective in people with alcohol use disorder -- something that has not yet been tested in clinical trials. The nausea profile of GDF15 is a practical hurdle here: a treatment that works but leaves patients persistently nauseated is unlikely to inspire much adherence.